daklinza
Pharmaranks rates Daklinza 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Daklinza (Daclatasvir Dihydrochloride) is a medication used to treat Chronic Hepatitis C.
Daclatasvir Dihydrochloride · by Bristol Myers Squibb
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Daclatasvir Dihydrochloride
- Form
- Tablet
- Strength
- Daclatasvir Dihydrochloride EQ 30MG Base · Daclatasvir Dihydrochloride EQ 60MG Base · Daclatasvir Dihydrochloride EQ 90MG Base
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- chronic hepatitis c
- Manufacturer
- Bristol Myers Squibb
- FDA application
- NDA206843
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Daklinza treat?
- Daklinza (Daclatasvir Dihydrochloride) may be used to treat chronic hepatitis c, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Daklinza rated?
- pharmaranks gives Daklinza a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Daklinza?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Daklinza. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Daklinza?
- Daklinza is marketed by Bristol Myers Squibb. You can see Bristol Myers Squibb's full profile, rating, and other products on pharmaranks.
- Is Daklinza a brand-name or generic drug?
- Daklinza is a brand-name product with the active ingredient Daclatasvir Dihydrochloride.
- Is Daklinza available over the counter?
- No. Daklinza is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Daklinza come in?
- Daklinza is currently marketed as tablet, per the FDA's National Drug Code Directory.
- Is Daklinza FDA-registered?
- Daklinza is on record with the U.S. FDA under application number NDA206843. You can verify this on its official FDA label.
- Has Daklinza been recalled by the FDA?
- Daklinza has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Daklinza safe?
- There's no single safe-or-not verdict. pharmaranks gives Daklinza a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about DACLATASVIR DIHYDROCHLORIDE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1,326 reports naming DACLATASVIR DIHYDROCHLORIDE — the active ingredient in Daklinza, and the FDA flagged 97% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- hepatocellular carcinoma120 reports
- hepatitis c95 reports
- treatment failure86 reports
- virologic failure84 reports
- viral mutation identified76 reports
- ascites62 reports
- fatigue57 reports
- headache53 reports
Read these as a signal, not a rate. A report does not mean DACLATASVIR DIHYDROCHLORIDE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Daklinza head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
daklinza
72/100